Top News

Roche immunotherapy Tecentriq fails trial in ovarian cancer


ZURICH (Reuters) - Swiss drugmaker Roche on Monday said a drug cocktail including its immunotherapy drug Tecentriq failed a late-stage trial in women with ovarian cancer when it did not increase survival without the disease progressing.

Roche said it was disappointed with the result of the trial, which added Tecentriq to the company's older drug Avastin as well as chemotherapy as a hopeful treatment against newly diagnosed advanced stage ovarian cancer.

(Reporting by John Miller, editing by Thomas Escritt)

Did this story inform or enhance your perspective on this subject?
1 being least likely, and 10 being most likely

Recent Stories